(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 12.14% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Exact Sciences's revenue in 2026 is $3,246,990,000.On average, 27 Wall Street analysts forecast EXAS's revenue for 2026 to be $715,067,238,406, with the lowest EXAS revenue forecast at $651,501,464,143, and the highest EXAS revenue forecast at $754,390,209,872. On average, 22 Wall Street analysts forecast EXAS's revenue for 2027 to be $803,830,256,521, with the lowest EXAS revenue forecast at $686,815,783,178, and the highest EXAS revenue forecast at $859,569,614,133.
In 2028, EXAS is forecast to generate $866,441,589,729 in revenue, with the lowest revenue forecast at $724,802,537,167 and the highest revenue forecast at $955,968,160,688.